The surprising therapeutic effect of the VRP-TRP2 vaccine as monotherapy in un-manipulated B16 tumor with these stringent conditions, prompted further investigation of the mechanism(s) underlying tumor immunity. The gene discussed is DCT; the disease is neoplasm.